Mithramycin represses MDR1 gene expression in vitro, modulating multidrug resistance

Biol Pharm Bull. 2000 Aug;23(8):926-9. doi: 10.1248/bpb.23.926.

Abstract

The effect of an aureolic acid, mithramycin (MTM) on multidrug resistance (MDR) was investigated. At a concentration of 0.02--0.1 mg/ml (about 20--90 microM), MTM repressed MDR1 gene transcription of SBC-3/ADM, a MDR-phenotype subline derived from human small cell lung tumor. Under the same conditions, another aureolic acid, chromomycin A3, showed potent cytotoxicity. FACS analysis revealed that 5 microm MTM depleted the P-glycoprotein (Pgp) and lowered the efflux activity of SBC-3/ADM cells. Furthermore, MTM sensitized the cells against adriamycin. These results suggest that MTM would be a useful modulator of MDR induced by Pgp.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Adult
  • Antineoplastic Agents / pharmacology
  • Base Sequence
  • DNA Primers
  • Doxorubicin / pharmacology
  • Drug Resistance, Multiple*
  • Gene Expression Regulation / drug effects*
  • Humans
  • Male
  • Plicamycin / pharmacology*
  • Transcription, Genetic / drug effects
  • Tumor Cells, Cultured

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • DNA Primers
  • Doxorubicin
  • Plicamycin